Anti-NCOA4 antibodies are immunoglobulins that specifically recognize and bind NCOA4, the gene encoding nuclear receptor coactivator 4 (also known as ARA70) in humans. In research applications, these antibodies are used to detect NCOA4 in tissue samples, cell lysates, and cultured cells. NCOA4 functions as a cargo receptor for the autophagic turnover of the iron-binding ferritin complex, delivering ferritin to lysosomes for degradation in a process called ferritinophagy that plays a central role in cellular iron homeostasis. Detecting NCOA4 supports research into iron metabolism and its connection to ferroptosis in cancer and tissue injury.
Catalog highlights and purchasing considerations
About the Biocompare NCOA4 antibody catalog
The Biocompare antibody search tool lists anti-NCOA4 antibodies from a range of suppliers, spanning unconjugated and fluorophore- or enzyme-conjugated formats. Listings may also appear under the alternate name ARA70. Western blot is the most common validated application among these listings, followed by immunohistochemistry and immunofluorescence. Several NCOA4 antibodies mentioned here have been cited across a range of iron metabolism research, including NCOA4-mediated ferritinophagy driving ferroptosis in acute lung injury, dietary suppression of KRAS-mutant pancreatic cancer through ferritinophagy-dependent ferroptosis, and homocysteine-induced ferritinophagy in macrophages.
Considerations when choosing an NCOA4 antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria warrant consideration, including clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method. Supplier validation data, such as western blot bands at the expected molecular weight, immunohistochemistry staining patterns consistent with known tissue distribution, and knockout or knockdown controls, should also be carefully reviewed before purchase.